Eptifibatide Acetate

Eptifibatide Acetate

Quick Details Description For the peptide (integrilin) is a new kind of polypeptide platelet glycoprotein Ⅱ b/Ⅲ a receptor antagonist, which inhibit platelet aggregation in the common way to inhibit platelet aggregation and thrombosis. Compared with monoclonal antibody acyclovir sheet...
Chat Now

Product Details

Quick Details


Product Name

Eptifibatide Acetate

CAS

188627-80-7

EINECS

1312995-182-4

Molecular Formula

C35H49N11O9S2

Molecular Weight

831.96

Application

For acute coronary syndrome and percutaneous coronary intervention

Purity

99%

storage

2 ~ 8 ℃ save


Description


For the peptide (integrilin) is a new kind of polypeptide platelet glycoprotein Ⅱ b/Ⅲ a receptor antagonist, which inhibit platelet aggregation in the common way to inhibit platelet aggregation and thrombosis. Compared with monoclonal antibody acyclovir sheet resistance, for the peptide due to a single conservative amino acid replacement replacement - lysine arginine, combination of GP Ⅱ b/Ⅲ a stronger, more directional and specificity. Therefore, it should have a good therapeutic effect in the interventional treatment of acute coronary syndrome.

Platelet glycoprotein Ⅱ b/Ⅲ a receptor antagonist drugs has developed a lot, at present there are three kinds of international can be used for clinical preparations, acyclovir single resistance (abciximab), for the peptide (eptifibatide) and for class had (tirofiban).

Domestic on platelet glycoprotein GP Ⅱ b/Ⅲ a receptor antagonist, little experience, the use of available drugs are very limited, only one kind of drug that class had listed for hydrochloric acid, thus the development of new platelet glycoprotein Ⅱ b/Ⅲ a receptor antagonist is imperative. The domestically produced ethabapeptides are imitations produced by chengdu suno biological products co., LTD.

indications

For acute coronary syndrome and percutaneous coronary intervention.


图片1

Inquiry